SAREPTA THERAPEUTICS INC
NASDAQ: SRPT (Sarepta Therapeutics, Inc.)
Kemas kini terakhir: 11 jam lalu20.11
-0.56 (-2.71%)
| Penutupan Terdahulu | 20.67 |
| Jumlah Dagangan | 6,292,130 |
| Harga / Pendapatan (P/E Ke hadapan) | 20.88 |
| Harga / Jualan (P/S) | 1.18 |
| Harga / Buku (P/B) | 1.43 |
| Julat 52 Minggu |
| Margin Keuntungan | -11.12% |
| Margin Operasi (TTM) | -40.33% |
| EPS Cair (TTM) | -2.64 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 80.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 248.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 118.73% |
| Nisbah Semasa (MRQ) | 4.02 |
| Aliran Tunai Operasi (OCF TTM) | -547.15 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -741.26 M |
| Pulangan Atas Aset (ROA TTM) | -2.19% |
| Pulangan Atas Ekuiti (ROE TTM) | -23.61% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Sarepta Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.5 |
| Purata | 0.44 |
|
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.42% |
| % Dimiliki oleh Institusi | 96.33% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Erste Asset Management Gmbh | 30 Jun 2026 | 2,568,945 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |